Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05620771 · ClinicalTrials.gov registry record · Phase 2
Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk
A Phase 2 study, sponsored by Northwestern University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
NCT05620771 is a Phase 2 study that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 200 participants.
The verdict
NCT05620771, a Phase 2 study, is actively recruiting participants, sponsored by Northwestern University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
Study Summary
The purpose of this research is to compare progression free survival between two available systemic therapies - immunotherapy and tyrosine kinase inhibitors - after Therasphere® (yttrium-90) treatment in adult patients with advanced hepatocellular carcinoma. The immunotherapy consists of a standard-of-care treatment with Atezolizumab and Bevacizumab. Treatment with tyrosine kinase inhibitors consists of standard-of-care Lenvatinib or Cabozantinib.
Interventions
- DRUG Y90 + Atezolizumab and Bevacizumab
- DRUG Y90 + TKI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2022-11-30 |
| Est. Completion | 2040-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05620771
The ClinicalTrials.gov registry entry for NCT05620771 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Y90 + Atezolizumab and Bevacizumab is the first listed.
NCT05620771 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05620771 about?
NCT05620771 is a clinical study titled "Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk". The purpose of this research is to compare progression free survival between two available systemic therapies - immunotherapy and tyrosine kinase inhibitors - after Therasphere® (yttrium-90) treatment in adult patients with advanced hepatocellular carcinoma. The immunotherapy consists of a standard-...
What is the current status of trial NCT05620771?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2022-11-30. Estimated completion is 2040-07-01.
What interventions are being tested in trial NCT05620771?
The interventions under investigation include: Y90 + Atezolizumab and Bevacizumab (DRUG), Y90 + TKI (DRUG).
Who is sponsoring clinical trial NCT05620771?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.